ASP Isotopes at Emerging Growth Conference 97: Scaling Critical Materials
5 days ago
At the Emerging Growth Conference 97, ASP Isotopes detailed its commercial growth strategy in helium, nuclear medicine, and semiconductor materials. Leveraging $250 million in cash, the company aims for $300 million EBITDA by 2031 through radiopharmacy acquisitions and a nanobody drug platform.
Show all 150 updates